ZyCoV-D® as a two-dose vaccine receives EUA from DCGI

article continues after this advertisement

Zydus Lifesciences Ltd., a discovery driven global lifesciences company announced that its novel COVID-19 vaccine, ZyCoV-D has received Emergency Use Authorisation (EUA) from the Drug Controller General of India (DCGI) as a two dose vaccine. With this approval, the vaccine will now be administered on day 0 and day 28. Earlier, the vaccine was approved in a three dose regimen to be administered on day 0, day 28 and day 56.

Earlier, the safety and efficacy analysis data from Phase III clinical trial of its Plasmid DNA COVID-19 vaccine ZyCoV-D (three dose regimen) has been peer reviewed and published in The Lancet, a reputed and well known medical journal. The results of the Phase I part of the Phase I/II clinical trial (three dose regimen) has also been published in the EClinical Medicine Journal of The Lancet.